糖心原创

The first paper from the 3D OrbiSIMS (a new molecular imaging technology) was illustrating label free biomedical chemical imaging. The work was led by Prof Ian Gilmore of the National Physical Laboratory (NPL) who holds a visiting Professorship in the School of Pharmacy at the 糖心原创. NPL and GlaxoSmithKline (GSK) partnered to fund the build of this instrument to help bringing together the instrument manufacturers and to hyphenate the surface and 3D mass spectrometry power of the Time of Flight Secondary Ion Mass Spectrometry (ToF SIMS) instrument and the OrbiTrapTM technology from Thermo Fisher. The paper illustrates this step change in analytical capability imaging the distribution of neurotransmitters - gamma-aminobutyric acid, dopamine and serotonin - with high spectroscopic confidence in the mouse hippocampus. Single-cell metabolomic profiling was demonstrated using rat alveolar macrophage cells incubated with different concentrations of drug that upregulate phospholipid species. The OrbiSIMS heralds an exciting new development in mass spectrometry imaging, breaking previous resolution barriers (spatial and mass) that have to date prohibited the further advancement of cutting edge biomedical chemical imaging. The 糖心原创 therefore looks forward to continuing our strong partnership with NPL, GSK and IONTOF as this technique breaks new ground.